Sökning: "immunoproteasome"

Hittade 4 avhandlingar innehållade ordet immunoproteasome.

  1. 1. Oligodendroglial (dys)function in alpha-synucleinopathies

    Författare :Carla Azevedo; Stamcellslaboratoriet för sjukdomsmodellering i det centrala nervsystemet; []
    Nyckelord :MEDICIN OCH HÄLSOVETENSKAP; MEDICAL AND HEALTH SCIENCES; Synucleinopathies; iPSCs; oligodendrocytes; alpha-synuclein; HLA; cell maturation; immunoproteasome;

    Sammanfattning : The complexity of a-synucleinopathies, which include multiple system atrophy (MSA) and Parkinson’s disease (PD), is not entirely understood. It is known that pathological accumulation of a-synuclein (a-syn) into proteinaceous aggregates is a cellular hallmark of these diseases. LÄS MER

  3. 2. Evaluating antitumoral lymphocytes for adoptive cell therapy : oxidative stress, neoantigen processing and co-stimulation

    Författare :Stefanie Marie Renken; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Rapid advancement in the field of immunotherapy has changed the treatment landscape of cancer, especially with the approval of immune checkpoint inhibitors for a wide range of cancer types. However, a large proportion of patients does not benefit from this treatment. LÄS MER

  4. 3. Neuroblastoma as a target for effector mechanisms of the immune system

    Författare :Anna De Geer; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :;

    Sammanfattning : Neuroblastoma (NB) is the most common solid extracranial tumor in children. Despite intensive multimodal treatment, the prognosis for high-risk NB patients remains poor and therefore new treatment modalities are needed. The main aim of my studies was to assess NB as a target for cytotoxic T lymphocyte (CTL)-mediated immunotherapy. LÄS MER

  5. 4. Strategies to optimize T cell-based cancer immunotherapy

    Författare :Simona Vertuani; Karolinska Institutet; Karolinska Institutet; []
    Nyckelord :MHC class 1; CTL; DNA vaccine; HER-2; Retinoic acid;

    Sammanfattning : Remarkable progress has been made in the field of tumor immunology in the past decade but active immunotherapy is not yet an established treatment modality. Tumor associated antigens (TAAs) presented in the form of peptides in association with MHC class 1 can be recognized by T cells and represent major targets of immunotherapy strategies to treat cancer patients. LÄS MER